Compare PHAR & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PHAR | TBPH |
|---|---|---|
| Founded | 1988 | 2013 |
| Country | Netherlands | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 993.7M |
| IPO Year | N/A | N/A |
| Metric | PHAR | TBPH |
|---|---|---|
| Price | $16.39 | $17.59 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $30.00 | $27.80 |
| AVG Volume (30 Days) | 21.0K | ★ 535.4K |
| Earning Date | 11-06-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | 0.00 | ★ 0.58 |
| Revenue | ★ $362,274,000.00 | $80,327,000.00 |
| Revenue This Year | $24.80 | $70.78 |
| Revenue Next Year | $6.84 | N/A |
| P/E Ratio | $3,084.39 | ★ $31.31 |
| Revenue Growth | 26.78 | ★ 27.12 |
| 52 Week Low | $7.50 | $7.90 |
| 52 Week High | $18.12 | $20.33 |
| Indicator | PHAR | TBPH |
|---|---|---|
| Relative Strength Index (RSI) | 49.79 | 49.22 |
| Support Level | $15.76 | $17.25 |
| Resistance Level | $18.12 | $18.36 |
| Average True Range (ATR) | 0.83 | 0.71 |
| MACD | -0.12 | -0.28 |
| Stochastic Oscillator | 28.81 | 10.59 |
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).